Pheochromocytoma as a catecholamine producing tumor: Implications for clinical practice

References

• Ahlman H. Malignant pheochromocytoma: State of the field with future projections. Ann NY Acad Sci 2006; 1073: 449–464
   PubMed Web of Science ®Google Scholar
• Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Munat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005a; 23: 8812–8818
   PubMed Web of Science ®Google Scholar
• Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005b; 90: 2110–2116
   PubMed Web of Science ®Google Scholar
• Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: Clinical observations from a Brooklyn tertiary hospital. Endocr Pract 2000; 6: 249–252
   PubMedGoogle Scholar
• Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: Effective treatment with combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988; 109: 267–273
   PubMed Web of Science ®Google Scholar
• Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann NY Acad Sci 2006; 1073: 30–37
   PubMed Web of Science ®Google Scholar
• Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003; 21: 1703–1707
   PubMed Web of Science ®Google Scholar
• Bausch B, Borozdin W, Neumann HP. European–American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006; 354: 2729–2731
   PubMed Web of Science ®Google Scholar
• Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006; 91: 827–836
   PubMed Web of Science ®Google Scholar
• Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma. Increasing importance for clinical decision making. Ann NY Acad Sci 2006; 1073: 94–103
   PubMed Web of Science ®Google Scholar
• Bravo EL, Tagle R. Pheochromocytoma: State-of-the-art and future prospects. Endocr Rev 2003; 24: 539–553
   PubMed Web of Science ®Google Scholar
• Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford RW, Jr. Clonidine-suppression test: A useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623–626
   PubMed Web of Science ®Google Scholar
• Brouwers FM, Eisenhofer G, Tao JT, Kant JA, Adams KT, Linehan WM, Pacak K. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: Implications for genetic testing. J Clin Endocrinol Metab 2006; 91: 4505–4509
   PubMed Web of Science ®Google Scholar
• Brouwers FM, Lenders JW, Eisenhofer G, Pacak K. Pheochromocytoma as an endocrine emergency. Rev Endocr Metab Disord 2003; 4: 121–128
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW, Pacak K. Pheochromocytomas in Von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86: 1999–2008
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K. Biochemical diagnosis of pheochromocytoma: How to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656–2666
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF, Jr. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer 2004a; 11: 423–436
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol Rev 2004b; 56: 331–349
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Goldstein DS, Sullivan P, Csako G, Brouwers FM, Lain EW, Adams KT, Pacak K. Biochemical and clinical manifestations of dopamine-producing paragangliomas: Utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005; 90: 2068–2075
   PubMed Web of Science ®Google Scholar
• Erickson D, Kudva YC, Ebersold MJ, Thompson GB, Grant CS, van Heerden JA, Young WF, Jr. Benign paragangliomas: Clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab 2001; 86: 5210–5216
   PubMed Web of Science ®Google Scholar
• Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann NY Acad Sci 2006; 1073: 465–490
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X. COMETE Network. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 2003; 63: 5615–5621
   PubMed Web of Science ®Google Scholar
• Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann HP, Opocher G, Maher ER, Plouin PF. European Network for the study of Adrenal Tumors (ENS@T) Pheochromocytoma Working Group Phaechromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 2006; 65: 699–705
   PubMedGoogle Scholar
• Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–318
   PubMed Web of Science ®Google Scholar
• Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, Reznek R, Sisson J, Eisenhofer G. Biochemical diagnosis and localization of pheochromocytoma: Can we reach a consensus?. Ann NY Acad Sci 2006; 1073: 332–347
   PubMed Web of Science ®Google Scholar
• Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138: 424–429
   PubMed Web of Science ®Google Scholar
• Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89: 479–491
   PubMed Web of Science ®Google Scholar
• Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, McElroy B, Pacak K. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 2003; 88: 4083–4087
   PubMed Web of Science ®Google Scholar
• Ito Y, Fujimoto Y, Obara T. The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 1992; 16: 759–764
   PubMed Web of Science ®Google Scholar
• John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: Can malignant potential be predicted?. Urology 1999; 53: 679–683
   PubMed Web of Science ®Google Scholar
• Kaplan NM. Pheochromocytoma (with a preface about incidental adrenal masses). Kaplan's clinical hypertension, NM Kaplan. Lipincott Williams & Wilkins, Philadelphia 2006; 389–409
   Google Scholar
• Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, Otto M, Cichocki A, Cwikla J, Slapa R, Eisenhofer G. 1111 Patients with adrenal incidentalomas observed at a single endocrinological center: Incidence of chromaffin tumors. Ann NY Acad Sci 2006; 1073: 38–46
   PubMed Web of Science ®Google Scholar
• Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Tisell LE, Ahlman H. Mortality associated with pheochromocytoma: Increased risk for additional tumors. Ann NY Acad Sci 2006; 1073: 444–448
   PubMed Web of Science ®Google Scholar
• Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359–369
   PubMed Web of Science ®Google Scholar
• Kuchel O, Buu NT, Racz K, De Lean A, Serri O, Kyncl J. Role of sulfate conjugation of catecholamines in blood pressure regulation. Fed Proc 1986; 45: 2254–2259
   PubMedGoogle Scholar
• Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP, Plouin PF. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clin Endocrinol (Oxf) 2002; 57: 629–634
   PubMed Web of Science ®Google Scholar
• Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Jr., Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell 2005; 8: 155–167
   PubMed Web of Science ®Google Scholar
• Lehnert H, Mundschenk J, Hahn K. Malignant pheochromocytoma. Front Horm Res 2004; 31: 155–162
   PubMed Web of Science ®Google Scholar
• Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: Which test is best?. JAMA 2002; 287: 1427–1434
   PubMed Web of Science ®Google Scholar
• Lenders JVM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665–675
   PubMed Web of Science ®Google Scholar
• Manger WM. The vagaries of pheochromocytoma. Am J Hypertens 2005; 18: 1266–1270
   PubMed Web of Science ®Google Scholar
• Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann NY Acad Sci 2006; 1073: 405–416
   PubMed Web of Science ®Google Scholar
• Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: A multicentric retrospective study. Eur J Endocrinol 1999; 141: 619–624
   PubMed Web of Science ®Google Scholar
• Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637–644
   PubMed Web of Science ®Google Scholar
• McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000; 30: 648–652
   PubMedGoogle Scholar
• Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE, Gauger PG. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?. Surgery 2003; 134: 918–922
   PubMed Web of Science ®Google Scholar
• Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, European–American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004; 292: 943–951
   PubMed Web of Science ®Google Scholar
• Nielsen JT, Nielsen BV, Rehling M. Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzylguanidine SPECT. Clin Nucl Med 1996; 21: 695–699
   PubMed Web of Science ®Google Scholar
• O'Riordain DS, Young WF, Jr., Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 1996; 20: 916–921
   PubMed Web of Science ®Google Scholar
• Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202
   PubMed Web of Science ®Google Scholar
• Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER. Genotype-phenotype correlations in Von Hippel–Lindau disease. Hum Mutat 2007; 28: 143–149
   PubMed Web of Science ®Google Scholar
• Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: Focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med 2005; 257: 60–68
   PubMed Web of Science ®Google Scholar
• Pešek J, Treška V, Ferda J, Mukenšnábl P. Images in cardiovascular medicine. Unusual case of pheochromocytoma with a surprising response to the intravenous administration of norepinephrine. Circulation 2005; 22: e327–e328
   Google Scholar
• Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29: 1133–1139
   PubMed Web of Science ®Google Scholar
• Proye C, Fossati P, Fontaine P, Lefebvre J, Decoulx M, Wemeau JL, Dewailly D, Rwamasirabo E, Cecat P. Dopamine-secreting pheochromocytoma: An unrecognized entity? Classification of pheochromocytomas according their type of secretion. Surgery 1986; 100: 1155–1162
   Web of Science ®Google Scholar
• Prys-Roberts C. Phaeochromocytoma—recent progress in its management. Br J Anaesth 2000; 85: 44–57
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–2300
   PubMed Web of Science ®Google Scholar
• Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH. CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol 2005; 15: 85–92
   PubMed Web of Science ®Google Scholar
• Sawka AM, Jaeschke R, Singh RJ, Young WF, Jr. A comparison of biochemical tests for pheochromocytoma: Measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553–558
   PubMed Web of Science ®Google Scholar
• Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Valimaki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, European–American Paraganglioma Study Group. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294: 2057–2063, Erratum in: JAMA 2006. 295. p. 628
   PubMed Web of Science ®Google Scholar
• Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: Imaging with Pheochromocytomas: Imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology 1999; 212: 35–41
   PubMed Web of Science ®Google Scholar
• Streeten DHP, Anderson GH, Jr. Mechanisms of orthostatic hypotension and tachycardia in patients with pheochromocytoma. Am J Hypertens 1996; 9: 760–769
   PubMed Web of Science ®Google Scholar
• Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW, Pacak K. Clinical presentations, biochemical phenotypes, and genotype–phenotype correlations in patients with SDHB-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2007; 2006–2315, doi: 10.1210/jc
   Web of Science ®Google Scholar
• Tsujimoto G, Honda K, Hoffman BB, Hashimoto K. Desensitization of postjunctional alpha 1- and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. Circ Res 1987; 61: 86–98
   PubMed Web of Science ®Google Scholar
• Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, Schmid KW, Mann K. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: Results of 161 tumors in 126 patients. World J Surg 2006; 30: 899–908
   PubMed Web of Science ®Google Scholar
• Weismann D, Fassnacht M, Weinberger F, Hamelmann W, Diehl S, Lorenz K, Baerlehner E, Reincke M, Beuschlein F, Knoefel W, Nies C, Hahner S, Allolio B. Intraoperative haemodynamic stability in patients with phaeochromocytoma-minimally invasive vs. conventional open surgery. Clin Endocrinol (Oxf) 2006; 65: 352–358
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Prinz RA, Onders RP, Solorzano CC. Analysis of large versus small pheochromocytomas: Operative approaches and patients outcomes. Surgery 2006; 140: 553–560
   PubMed Web of Science ®Google Scholar
• Zelinka T, Štrauch B, Pecen L, Widimský J, Jr. Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing's syndrome. J Hum Hypertens 2004; 18: 107–111
   PubMed Web of Science ®Google Scholar
• Zelinka T, Štrauch B, Petrák O, Holaj R, Vranková A, Weisserová H, Pacák K, Widimský J, Jr. Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. J Hypertens 2005; 23: 2033–2039
   PubMed Web of Science ®Google Scholar
• deS Senanayake P, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995; 96: 2503–2509
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006; 47: 1599–1606
   PubMed Web of Science ®Google Scholar
• van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86: 685–693
   PubMed Web of Science ®Google Scholar
• van der Horst-Schrivers AN, Kerstens MN, Wolffenbuttel BH. Preoperative pharmacological management of phaeochromocytoma. Neth J Med 2006; 64: 290–295
   PubMed Web of Science ®Google Scholar